FindTrial
Sign In

Study of Diagnostic marker for anemia

Study on Reticulocyte Hemoglobin Content (CHr) In Chronic Renal Disease Patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/092038
Enrollment
345
Registered
2025-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs Health Condition 2: D758- Other specified diseases of bloodand blood-forming organs

Interventions

Intervention1: Testing of Reticulocyte Hemoglobin Content For Anemia in CKD Patients: Study Design Prospective Observational Cohort Study Study Duration 12 Months Follow up at 0 3 6 9 and 12 months St

Sponsors

Safia Hasan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Chronic Kidney Disease (CKD), stages 2 5 2. Hemoglobin level less than 11 gm /dl 3. Nno Dialysis Patient

Exclusion criteria

Exclusion criteria: Active bleeding or recent transfusion within 3 months Malignancy or active inflammation Non CKD hematologic disorders Pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
Time to anemia development Hb Less than 13 gdL for men Less than 12 gdL for women in relation to baseline CHr levelsTimepoint: 4 weeks—

Secondary

MeasureTime frame
Secondary Outcomes Sensitivity & specificity of CHr Less than 29 pg for predicting anemia Correlation of CHr with Hb ferritin TSAT CHr ability to monitor iron ESA therapy responsesTimepoint: 6 to 8 weeks—

Countries

India

Contacts

Public ContactSafia Hasan

Sardar Bhagwan Singh University

poojabamrara_2007@yahoo.co.in9897298627

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026